Drug Type Autologous CAR-T |
Synonyms Autologous T-cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a, CD1a-CAR T(OneChain Immunotherapeutics), CD1a-CAR-T (OneChain) + [4] |
Target |
Mechanism CD1A modulators(CD1a molecule modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-cell Acute Lymphoblastic Leukemia/Lymphoma | Preclinical | US | 05 Sep 2023 |